Life Sciences

  • October 26, 2026

    Novo Can't Get 'Deceptive' Lilly GLP-1 Ads Blocked Amid Suit

    A New Jersey federal judge on Monday refused to issue an injunction blocking Eli Lilly & Co. from running ads allegedly comparing its GLP-1 drug to Novo Nordisk Inc.'s using "outdated" clinical trials and "false superiority messages," ruling that Novo Nordisk hasn't shown it would be irreparably harmed.

  • October 26, 2026

    Feds Say States Lack Standing To Sue Over HHS Vax Overhaul

    The Trump administration is again asking a California federal judge to toss a coalition of states' lawsuit challenging its decision to cut vaccine recommendations for children, arguing that the states cannot show harm that gives them standing to sue.

  • October 26, 2026

    Nomi Says HHS Shirked COVID Care Reimbursement Promise

    Utah-based Nomi Health Inc. sued the U.S. government on Friday, claiming that it failed to provide more than $200 million in promised payments for testing and vaccination services provided to uninsured Americans during the COVID-19 pandemic.

  • October 26, 2026

    3 Firms Steer Obesity Drugmaker Corxel's $377M SPAC Deal

    Obesity-focused biopharmaceutical company Corxel Pharmaceuticals Inc. on Monday unveiled plans to go public by merging with special-purpose acquisition company Amanat Acquisition Corp. in a deal expected to generate roughly $377 million in gross proceeds and that was built by three law firms.

  • October 26, 2026

    In 2/3 Generics Cases, Mylan Execs Allowed To Revoke 5th

    A Connecticut federal judge carved a different path Friday for two later generic-drug price-fixing cases from state attorneys general, allowing Mylan executives to revoke their previous invocation of the Fifth Amendment unimpeded, after previously allowing the enforcers to challenge that revocation in the first case set for trial.

  • October 26, 2026

    Bristol-Myers, Others Appeal Revlimid MDL To 3rd Circ.

    Bristol-Myers Squibb, Natco Pharma, AbbVie and other pharmaceutical companies have sought permission to file an interlocutory appeal for a sprawling antitrust multidistrict litigation over Celgene Corp.'s cancer drug Revlimid to the Third Circuit after a New Jersey federal judge refused to toss it.

  • October 26, 2026

    Radiology Co. Strikes Deal In ESOP Fight Ahead Of Trial

    Radiology company Envision and its trustee have settled a class action claiming they brokered an inflated $163.7 million stock sale to the business' employee stock ownership plan, staving off a bench trial that was days away from kicking off, according to a Colorado federal court filing.

  • October 23, 2026

    Teva, Eli Lilly Spar Over Possible New Drug Patent Trial

    Eli Lilly and Teva on Friday sparred over whether a new trial should be held in Massachusetts federal court over the validity of patents related to Teva's migraine drug Ajovy after the Federal Circuit reversed the Boston court's judgment that favored Eli Lilly.

  • October 23, 2026

    Eli Lilly, Novo Nordisk Antitrust Suit Remains Dismissed

    A Texas federal judge has denied Strive Specialties Inc.'s bid to undo her judgment dismissing the compounding pharmacy's lawsuit that accuses Eli Lilly and Novo Nordisk of blocking competition for GLP-1 medications, saying Strive's claim that the court committed a manifest legal error was based on the company's own misunderstanding.

  • October 23, 2026

    Consumers Fight Bids To End Delta-8 Mislabeling Suit

    Vape maker Savage Enterprises, two distributors and a California testing lab must not be allowed to shake a lawsuit accusing them of trying to pass off vape pens with illegal levels of THC as legal hemp products, consumers told an Arkansas federal court, saying their dismissal bids are moot because there is a new complaint.

  • October 23, 2026

    J&J Wins Ohio Talc Mesothelioma Trial

    An Ohio state jury on Friday found in Johnson & Johnson's favor in a wrongful death suit brought by the family of a woman who alleged that her mesothelioma was caused by her longtime use of talc cosmetic products containing asbestos.

  • October 23, 2026

    Del. Forum Selection Clause Sinks IQVIA's NC Poaching Suit

    IQVIA Holdings Inc. should have brought its poaching suit against four former employees accused of defecting to a competitor in Delaware court under a forum selection clause in their employment contracts, a North Carolina Business Court judge ruled Thursday in dismissing the case.

  • October 23, 2026

    Alembic Settles With Vanda Over Schizophrenia Drug Generic

    Vanda Pharmaceuticals and Alembic Pharmaceuticals notified a Delaware federal judge Friday that they have settled a patent dispute over Alembic's planned generic version of Vanda's schizophrenia drug Fanapt.

  • October 23, 2026

    Baxter Says Novum Pump Issues Don't Show Securities Fraud

    A group of Baxter International shareholders should not be allowed to pursue securities fraud claims over a new fluid pump product later deemed defective simply because the product and its revenues performed worse than publicly expected, the company and its executives have told an Illinois federal judge.

  • October 23, 2026

    Generics MDL Judge Won't Extend Pause Over Conflict

    A Pennsylvania federal judge refused Friday to extend a pause on the generic-drug price-fixing multidistrict litigation, eyeing setting a new trial date for the first bellwether case initially paused by a conflict with a special master that the drugmakers say now covers "the entire MDL."

  • October 23, 2026

    Insulet Can't Keep Injunction During Trade Secret Appeal

    The Federal Circuit has denied insulin product developer Insulet Corp.'s request to keep an injunction in place against rival EOFlow Co. Ltd. while it appeals an axed $59 million trade secrets jury verdict to the U.S. Supreme Court.

  • October 23, 2026

    AI Cardiac Imaging Co. Heartflow Files IP Suit Against Rival

    Artificial intelligence-powered cardiac imaging company Heartflow Inc. is accusing a competitor of infringing its patents covering a noninvasive heart test and luring almost a dozen of its employees to make a similar product.

  • October 23, 2026

    Fenwick, Cooley Steer Lycia Therapeutics' Upsized $318M IPO

    Early-stage biotechnology firm Lycia Therapeutics began trading Friday after raising $318 million in its upsized initial public offering steered by Fenwick & West LLP and Cooley LLP.

  • October 23, 2026

    Ultrahuman Sued By Ouraring Again After Redesign Win

    Smart ring-maker Ouraring Inc. has filed another lawsuit against rival Ultrahuman Healthcare Inc., asserting two patents it said were not addressed in an earlier suit that resulted in an import ban that was later lifted when Ultrahuman redesigned its product.

  • October 23, 2026

    Taxation With Representation: Milbank, De Brauw, Wachtell

    In this week's Taxation With Representation, EQT Private Equity announces a takeover offer for life sciences testing company Qiagen NV, Salesforce acquires customer engagement platform Braze and London Stock Exchange Group buys U.S. credit intelligence provider Octus.

  • October 23, 2026

    US Opens Duty Investigations Into Chinese Compounds

    The U.S. Department of Commerce is opening investigations into whether certain chemical compounds imported from China are being sold at less than fair value and are subsidized, the department said Friday.

  • October 22, 2026

    Nestle's Solgar Has Dangerous Vitamin B6 Levels, Suit Says

    Nestle was hit with a proposed false advertising class action Wednesday in New Jersey federal court alleging its Solgar VM-75 supplements contain dangerous levels of vitamin B6, which can heighten the risk of developing peripheral neuropathy or worsen the condition.

  • October 22, 2026

    DEA Judge Will Not Reopen Marijuana Rescheduling Hearing

    The coalition fighting marijuana legalization won a partial victory after a Drug Enforcement Administration's administrative law judge on Thursday allowed into the record a U.S. Government Accountability Office report the group championed but denied new testimony on it, saying the report "speaks for itself."

  • October 22, 2026

    Gilead Reaches $45M Settlement To End Kickback Claims

    The Texas Office of the Attorney General on Thursday announced that pharmaceutical company Gilead Sciences Inc. signed off on a $45 million settlement to end claims that the company ran an illegal kickback scheme in order to get prescribers to favor its medications.

  • October 22, 2026

    Elsevier Beats Defamation Suit Over Air Purifier Article

    An indoor air quality company failed to prove academic publisher Elsevier acted with malice in printing an article questioning the effectiveness of its air purification technology sufficient to sustain a claim for defamation, a North Carolina federal judge ruled Thursday.

Expert Analysis

  • Cannabis, Psychedelics Boom Raises IP Hurdles

    Author Photo

    Recent data regarding patent filing activity and litigation in the cannabis and psychedelics markets indicates that as commercial interest accelerates, the scope of publicly accessible prior art is also expanding, setting a higher bar for novelty and nonobviousness in patent applications, say attorneys at Sterne Kessler.

  • State AI Safety Laws Raise New Liabilities For Healthcare Cos.

    Author Photo

    Healthcare and life science companies using third-party artificial intelligence tools should pay particular attention to the changing state-level legal landscape, where the rollout of multiple AI safety laws is introducing both new compliance obligations and potential consumer protection liabilities, say attorneys at McDermott.

  • Series

    Juggling And Unicycling Make Me A Better Lawyer

    Author Photo

    Because I juggle (sometimes with fire) and ride the unicycle, friends and family used to joke that I should join the circus, but I pursued the practice of law instead and learned that my hobbies benefit my profession in several important ways, says Morgan Eddy at Smith Currie.

  • AI Note-Taking Suits May Fill Gap In Privacy Law Structure

    Author Photo

    A recent class action against Granola joins other pending lawsuits against AI note-taking providers, highlighting the legal uncertainty surrounding these tools, but there are practical steps companies using "invisible" AI services can take to mitigate risk, including conducting inventories and reviewing access permissions, say attorneys at Barnes & Thornburg.

  • FDA Closeout Letter Suggests Relaxing Stance On Wearables

    Author Photo

    The U.S. Food and Drug Administration's recent decision not to pursue enforcement action against Whoop's wearable blood pressure tracker, read together with guidance released earlier this year, suggests a softer shift in the FDA's approach to regulating wearables, say attorneys at Arnold & Porter.

  • Fed. Circ. Dental IP Ruling Reinforces Prior Art Framework

    Author Photo

    The Federal Circuit's recent decision in Dental Monitoring v. Align Technology reaffirms the necessity of substantive written description support for establishing an earlier effective prior art date under the America Invents Act, and aligns Patent Trial and Appeal Board practice with district court litigation, say attorneys at Morgan Lewis.

  • Justices' Hikma Reasoning May Extend Well Beyond Pharma

    Author Photo

    The active steps framework announced by the U.S. Supreme Court in its Hikma v. Amarin decision, finding that Amarin failed to plausibly allege inducement of infringement, has the potential to reshape how courts evaluate inducement claims across patent, copyright and other doctrines, say attorneys at BCLP.

  • Teva MDL Loss Shows DPAs Can Return To Haunt Civil Suits

    Author Photo

    Teva’s recent partial summary judgment loss in antitrust multidistrict litigation reinforces the importance of carefully scrutinizing any statement of facts a company admits to in a deferred prosecution agreement, and illustrates the potential costs of resolving a criminal investigation this way, say attorneys at Sheppard.

  • An Inside Look At Squires' Discretionary Denials

    Author Photo

    A deep dive into the discretionary denials issued by U.S. Patent and Trademark Office Director John Squires since he took over last year identifies trends in commonly asserted arguments and how they correlate with institution outcomes, say attorneys at Kirkland & Ellis.

  • Series

    Ballet Makes Me A Better Lawyer

    Author Photo

    A lifetime of learning and performing ballet taught me that success — whether in dance or practicing law — comes only through hours of thorough preparation, boundless energy and relentless effort, says Sharon Katz-Pearlman at Greenberg Traurig.

  • Fed. Circ. In July: Meeting The Enablement Requirement

    Author Photo

    The Federal Circuit's decision in Wyeth v. AstraZeneca last month exemplifies when a generalized conception of an invention is insufficient to enable the full scope of asserted patent infringement claims, and may lead to more enablement challenges, say attorneys at Knobbe Martens.

  • Series

    Taekwondo Makes Me A Better Lawyer

    Author Photo

    Taekwondo has taught me to recognize when to fight for a position and when to focus on finding a solution, and that the best outcomes are often achieved by solving problems — all of which has improved my work as a bankruptcy lawyer, mediator and Subchapter V trustee, says Amy Denton Mayer at Berger Singerman.

  • Why AI Diligence Is Especially Key In IP Practice

    Author Photo

    In light of recent federal court sanctions against intellectual property litigators for filing work product generated by artificial intelligence without verification, it's important to consider the unique risks and consequences that can arise from overreliance on AI, which poses less visible risks in IP matters, says Stephen Ball at Husch Blackwell.

  • How 'Most Favored Nation' Regime Affects Biopharma Deals

    Author Photo

    As M&A activity surges in the biopharma space, companies will need to account for the Trump administration's most-favored-nation pricing proposals — durable in concept, if unsettled in detail — when drafting deals, say attorneys at Gibson Dunn.

  • What To Know As Legal Duty To Consider AI Takes Shape

    Author Photo

    While the U.K. Jurisdiction Taskforce’s recent statement on liability for artificial intelligence harms is nonbinding for both U.K. and U.S. lawyers, it highlights the importance of being able to distinguish between the availability of a tool and a professional obligation to use it, say Jonny Frank and Michael Costa at StoneTurn.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.